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at www.jvascsurg.org.DISCUSSIONDr John Hallett (Charleston, SC). First, let me thank the Pro-
gram Committee for the privilege to comment on this important
presentation. And thanks to Dr Hogendoorn, Dr Sumpio, and col-
leagues for allowing me to peruse their manuscript before their
presentation.
In the past 20 years, the improvements in mesenteric ultra-
sound and the wider use of computed tomography mesenteric
angiography have revealed the larger size of this vascular
“iceberg.” Chronic mesenteric ischemia is much more prevalent
that we imagined. This sophisticated analysis comes at a time
when we all need management guidance based on all the evidence.
Four general questions come to mind in reviewing any paper.
First, can one summarize the message clearly in a sentence or two?
Second, have the methods been appropriate, even innovative, in
deriving the conclusions? Third, does the information offer any-
thing new to help in the care of patients? And ﬁnally, what is
next? How do we use this information to advance the science
and care of our vascular patients?Before comment is made on these four general questions, let
us remember the remarkable evolution, in less than a century, of
the recognition and management of chronic mesenteric ischemia.
Mesenteric ischemia was ﬁrst recognized in the 15th century in
Florence, Italy. For the next four centuries, postmortem studies
stressed that the “pre-mortem diagnosis is impossible, the prog-
nosis hopeless, and the treatment almost useless.”
In 1936, Dunphy, a Harvard surgical resident, made the
prescient observation that many patients who died of ischemic
gut infarction due to superior mesenteric artery (SMA) athero-
sclerosis had a typical history of postprandial abdominal pain
that was not called “intestinal angina” until 1956. In 1958,
Shaw at the Massachusetts General Hospital performed the ﬁrst
successful surgical SMA thromboendarterectomy. Subsequently,
Morris in Houston performed the ﬁrst successful surgical
bypass to the SMA in 1962. Working in San Francisco, Stoney
and Wylie perfected the transaortic thromboendarterectomy
by 1966.
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ment in the 1980s with their observation that long-term results
appeared better when more than one diseased mesenteric was
revascularized.
In 1980, Ferrer and Gruntzig reported the ﬁrst endovascular
dilation of the SMA.
All of these contributions over time must be considered as we
look at the currently proposed Markov decision model.
Now we come to the answers to the four key questions.
The single most important message from this sophisticated
study is that endovascular therapy is preferable in both effec-
tiveness and cost to surgical intervention at nearly every age.
Endovascular therapy has ﬁve times the rate of reintervention,
but this appears to be a reasonable tradeoff, considering the
relatively high mortality and morbidity of mesenteric artery
surgery.
Second, the Markov decision model is a proven method for
offering clinicians some guidelines about any intervention, at
various ages and with various risk factors. This model appears to
support the clinical observation and shifts in mesenteric therapy
that we have experienced in the past decade.
Third, this current model should help us all to inform our pa-
tients about the safer options for chronic mesenteric ischemia. But
in the end, I worry whether every vascular program will continue
to have a team capable of both endovascular therapy and surgical
intervention. We still need both options. Both require some
advanced skills that need to be focused on a few physicians and sur-
geons who do this frequently.
Finally, what is next? Could the authors comment on the
following?1. Is there enough data coming forward to ascertain when stent
angioplasty should be used over simple angioplasty? And, what
stent?
2. Do you really recommend that we consider a multicenter ran-
domized trial to evaluate angioplasty vs surgical revasculariza-
tion? That would be a very expensive and time-consuming trial.
3. Would it not be more reasonable to recommend that the
Vascular Quality Initiative consider a module to track the
treatment of both acute and chronic mesenteric ischemia
and outcomes? We would learn quickly what is really working.
Again, we all should appreciate the important value of this
Markov model in providing rational guidance in the management
of the increasingly recognized cases of chronic mesenteric
ischemia. The Medicare population doubles in the next decade,
and this challenging clinical entity is likely to be at our doorstep
ever more frequently.
Dr Wouter Hogendoorn. Thank you for your comments
and interesting questions. I also thank you for the historical over-
view. First, decision analysis is particularly useful when there is a lot
of clinical data but from small studies and when there are no ran-
domized controlled trials to guide treatment. Decision models
analyze the outcomes from these small studies and can provide
useful information for a speciﬁc patient on the basis of his or her
risk proﬁle. We envision the potential of creating an app or a chart
where this information can be stored and used by the surgeon and
patient to predict outcomes for the various treatment options.
Last, we agree that performing a randomized controlled trial is
difﬁcult and costly, and decision analysis may be the optimum
method for use of the clinical data that is already available.
